Soluble amyloid-beta buffering by plaques in Alzheimer disease dementia versus high-pathology controls
Fig 3
Assessments based on confocal fluorescence microscopy of Aβ1-42-biotin binding does not distinguish between elderly high-pathology controls and elderly subjects with mild ADD.
(A) Gray matter coverage of fluorescently labelled (streptavidin-Alexa594) Aβ1-42-biotin binding in CDR 0 + plaques group versus CDR 1 group (not significant [n.s.] by Mann–Whitney U test). (B) Correlations between fluorescently labelled Aβ1-42-biotin gray matter coverage and overall Aβ plaque coverage. (C) Ratio of the normalized fluorescently labelled Aβ1-42-biotin signal to the percentage fluorescent positive coverage (not significant [n.s.] by Mann–Whitney U test).